TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Beta-Cell Function After Near-Normalisation of Blood Glucose

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-70 years~* Type 2 diabetes diagnosed after 30 years of age~* BMI \> 25~Exclusion Criteria:~* Severe complications to diabetes~* Abnormal liver and kidney function~* Haemoglobin below the lower limit~* Macroalbuminuria~* Systemic disease~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- GLP-1 (Type: EXPERIMENTAL): None
- GIP (Type: EXPERIMENTAL): None
- saline (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy Trial of Electroacupuncture at Points of Bilateral BL33 for Mild and Moderate Benign Prostatic Hyperplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 50-70 years old~* Mild to moderate BPH evaluated by I-PSS~* Patients having urinary dysfunction more than 3 months~* Patients with stable life signs~* no use of α1 receptor blocker, 5α-reductase inhibitor or traditional Chinese medicine for over 1 week~* Volunteer to join this research and sign the written informed consent prior to receiving treatment~Exclusion Criteria:~* Urinary dysfunction caused by gonorrhea or urinary tract infection~* Oliguria and anuria caused by urinary calculi, prostate cancer, bladder tumor and acute/chronic renal failure~* Urinary dysfunction caused by neurogenic bladder, bladder neck fibrotic and urethral stricture~* Failure of invasive therapy for prostatic obstruction~* Injured local organs, muscle and nerve caused by pelvic operation or historical trauma~* Upper urinary obstruction and hydrocele combined with damaged renal function due to BPH diagnosed by B-ultrasound~* Patients who can't stick to treatment because of economic reason, far distance between home and the hospital or difficult walking etc.

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- acupoint (Type: EXPERIMENTAL): Needle at bilateral BL33 60-80 mm with a 45°angle.A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3).Needle with a 100-125 mm long needle without lifting, thrusting or rotating.G6805-2 electric stimulator (produced by Shanghai Huayi Medical Instrument Co.Ltd)is put on with Sparse-dense wave,20Hz. Stop turning up the current intensity when patients could not stand. There are 5 sessions in the first two weeks and 3 sessions in the last two weeks, 30 min/session.
- non-acupoint (Type: SHAM_COMPARATOR): Take the place 2 cun far from BL33 on the outside horizontally as the non-point. Needle on the non-point for 60-80mm with a 45°angle. A feeling of soreness and distension will be felt .Needle with a 100-125mm long needle without lifting, thrusting or rotating.Sparse-dense wave,20Hz. Stop turning up the current intensity when patients could not stand. 5 times for the first two weeks and 3 times for the last two weeks, 30 min/time.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria~* Males or females, aged 18 - 70 years~* Recipients of de novo cadaveric, living unrelated or living related kidney transplants~* Females capable of becoming pregnant must have a negative serum pregnancy test within 7 days prior to or at screening, and are required to practice an approved method of birth control for the duration of the study and for a period of 6 weeks following discontinuation of study medication, even where there has been a history of infertility.~* Patients who are willing and able to participate in the study and from whom written informed consent has been obtained.~Exclusion criteria~* More than one previous renal transplantation~* Multi-organ recipients (e.g., kidney and pancreas) or previous transplant with any other organ, different from kidney~* Patients receiving a kidney from a non-heart beating donor~* Donor age: \< 5 years or \> 70 years~* Graft loss due to immunological reasons in the first year after transplantation (in case of secondary transplantation)~* Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- CNI standard regimen (Type: ACTIVE_COMPARATOR): Myfortic, Sandimmun Optoral and corticosteroids
- CNI free regimen (Type: EXPERIMENTAL): CNI free regimen: comprising the following steps for switching treatment:~Step 1 at BL2 + 1 day: Myfortic, Certican 1.5 mg, Sandimmun Optoral (50% of standard dose) and corticosteroids Step 2 at BL2 + 8 days: Myfortic, Certican 3 mg and corticosteroids
- CNI low regimen (Type: ACTIVE_COMPARATOR): CNI low regimen: comprising the following steps for switching treatment:~Step 1 at BL2 + 1 day: Certican 1.5 mg, Sandimmun Optoral and corticosteroids Step 2 at BL2 + 8 days: Certican 1.5 mg, Sandimmun Optoral (low dose) and corticosteroids

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PT005 MDI Dose Ranging Versus Foradil Aerolizer Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Key Inclusion Criteria:~* Signed written informed consent~* 40 - 80 years of age~* Clinical history of COPD with airflow limitation that is not fully reversible~* Females of non-child bearing potential or females of child bearing potential with negative pregnancy test; and acceptable contraceptive methods~* Current/former smokers with at least a 10 pack-year history of cigarette smoking~* A measured post- bronchodilator FEV1/FVC ratio of \< or = 0.70~* A measured post- bronchodilator FEV1 \> or = 750ml or 30% predicted and \< or = 80% of predicted normal values~* Able to change COPD treatment as required by protocol~* Demonstratead reversibility to short acting beta agonist (Ventolin HFA) (\> 12% and \>150 mL improvement in baseline FEV1 approximately 30 minutes following administration of 4 puffs of Ventolin HFA or \> 200 mL improvement in baseline FEV1 30 minutes following administration of 2 puffs of Ventolin HFA)~Key Exclusion Criteria:~* Women who are pregnant or lactating~* Primary diagnosis of asthma~* Alpha-1 antitrypsin deficiency as the cause of COPD~* Active pulmonary diseases~* Prior lung volume reduction surgery~* Abnormal chest X-ray (or CT scan) not due to the presence of COPD~* Hospitalized due to poorly controlled COPD within 3 months of Screening~* Clinically significant medical conditions that preclude participation in the study (e.g. clinically significant abnormal ECG, uncontrolled hypertension, glaucoma, symptomatic prostatic hypertrophy)~* Cancer that has not been in complete remission for at least 5 years~* Treatment with investigational study drug or participation in another clinical trial or study within the last 30 days or 5 half lives~Other inclusion/exclusion criteria as defined by the protocol

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- PT005 MDI (Dose 1) (Type: EXPERIMENTAL): PT005 MDI (Dose 1)
- PT005 MDI (Dose 2) (Type: EXPERIMENTAL): PT005 MDI (Dose 2)
- PT005 MDI (Dose 3) (Type: EXPERIMENTAL): PT005 MDI (Dose 3)
- Placebo MDI (Type: PLACEBO_COMPARATOR): Placebo MDI
- Formoterol Fumarate 12 μg (Foradil® Aerolizer®) (Type: ACTIVE_COMPARATOR): Formoterol fumarate inhalation powder 12 μg
- Formoterol Fumarate 24 μg (Foradil® Aerolizer®) (Type: ACTIVE_COMPARATOR): Formoterol fumarate inhalation powder 24 μg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Octaplas Pediatric Plasma Replacement Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient requiring liver or cardiac surgery and/or patient with liver dysfunction associated with coagulopathy in whom replacement of multiple coagulation factors is required.~2. Voluntarily given, written and signed informed consent by the patient's legal representative(s) or guardian(s). Children deemed old enough by the Investigator/institution to understand the risks and benefits of the study should also be made aware of the risks/benefits of the study and provide written assent.~3. Male or female patient ≤ 16 years of age.~Exclusion Criteria:~1. Patient with known homozygous congenital deficiency of protein S.~2. Patient has a history of hypersensitivity reaction to blood or plasma-derived products or to any excipient of the investigational product.~3. Patient has an already known IgA (Immunoglobulin A) deficiency with documented antibodies against IgA.~4. Patient has a congenital factor deficiency or platelet disorder requiring plasma treatment.~5. Patient is currently participating in another study investigating a new drug product or another interventional clinical study that may impact coagulation factors or has participated during the last three (3) months.~6. Patient received FFP (Fresh Frozen Plasma), FP24 (Plasma frozen within 24 hours of collection) or any other plasma product other than Octaplas within the last 72 hours (cryoprecipitate and albumin are not exclusionary) prior to first Octaplas infusion.~7. Patient is on ECMO (Extracorporeal Membrane Oxygenation) when plasma is ordered by the treating physician for the first infusion episode.~8. Patient is pregnant.~9. Patient is predicted to require massive blood transfusion defined as more than 40 mL per kilogram of all blood products in a 24-hour period~10. Patient is receiving plasma exchange, therapeutic plasma exchange (TPE) or plasmapheresis.~11. Patient is a premature neonate defined as less than 37 weeks gestation.~12. Cardiac surgery patients who develop the need for plasma replacement greater than 72 hours after the end of the associated cardiac surgery and do not have coagulopathy due to hepatic dysfunction.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Octaplas (Type: EXPERIMENTAL): Qualified patients will receive Octaplas as per protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Neural Stimulation in Individuals With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age = 18-64~* Diagnosed with schizophrenia or schizoaffective disorder~* Having current (in the past week) or recent (in the past month) paranoia~Exclusion Criteria:~* Presence or history of a pervasive developmental disorder or mental retardation as defined by IQ \< 70~* Presence or history of neurological or medical disorders that contraindicate neural stimulation (e.g. presence or history of epilepsy, seizures, etc.)~* Demonstrating sensory limitations, including uncorrectable visual or hearing impairments that interfere with assessment~* History of electroconvulsive therapy~* Lack of proficiency in English~* Substance use disorder not in remission in the past 6 months~* Any implanted devices such as pace maker, neurostimulator~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Active anodal tDCS first, then Sham tDCS (Type: EXPERIMENTAL): Active anodal tDCS (40 minutes; divided into two 20-minutes sessions) followed by behavioral testing; Washout (about 1 week); sham stimulation (40 minutes; divided into two 20-minutes sessions) followed by behavioral testing.
- Sham tDCS first, then Active anodal tDCS (Type: SHAM_COMPARATOR): Sham tDCS (40 minutes; divided into two 20-minutes sessions) followed by behavioral testing; Washout (about 1 week); Active anodal tDCS (40 minutes; divided into two 20-minutes sessions) followed by behavioral testing Intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Male, aged 12 to 65 years~* Severe hemophilia A~* History of more than 150 exposure days (ED) with clotting factor concentrates~* Currently receiving episodic treatment with FVIII; no regular prophylaxis for more than 6 consecutive months in the past 5 years~* No current Factor VIII inhibitor or history of inhibitor~* Willing to use electronic patient diary~Exclusion Criteria:~* Presence of another bleeding disease that is different from hemophilia A~* Thrombocytopenia~* Abnormal renal function~* Presence of active liver disease~* Known hypersensitivity to FVIII

- Gender: MALE
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1: rFVIII on demand first CS/EP then CS/ADJ (Type: EXPERIMENTAL): Participants received on-demand treatment with recombinant factor VIII (rFVIII, BAY81-8973) assayed by CS/EP (Chromogenic Substrate Assay per European Pharmacopoeia) for 6 months, followed by cross-over to study drug assayed by CS/ADJ (Chromogenic Substrate Assay/label adjusted to one-stage assay) for 6 months.
- Arm 2: rFVIII on demand first CS/ADJ then CS/EP (Type: EXPERIMENTAL): Participants received on-demand treatment with rFVIII (BAY81-8973) assayed by CS/ADJ for 6 months, followed by cross-over to study drug assayed by CS/EP for 6 months.
- Arm 3: rFVIII prophylaxis low-dose first CS/EP then CS/ADJ (Type: EXPERIMENTAL): Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII(BAY81-8973) measured by CS/ EP for 6 months then crossed over to study drug measured by CS/ADJ for 6 months.
- Arm 4: rFVIII prophylaxis low-dose first CS/ADJ then CS/EP (Type: EXPERIMENTAL): Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII (BAY81-8973) measured by CS/ADJ for 6 months then crossed over to study drug measured by CS/ EP for 6 months.
- Arm 5: rFVIII prophylaxis high-dose first CS/EP then CS/ADJ (Type: EXPERIMENTAL): Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII (BAY81-8973) measured by CS/ EP for 6 months then crossed over to study drug measured by CS/ADJ for 6 months.
- Arm 6: rFVIII prophylaxis high-dose first CS/ADJ then CS/EP (Type: EXPERIMENTAL): Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII(BAY81-8973) measured by CS/ADJ for 6 months then crossed over to study drug measured by CS/ EP for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Irinotecan Hydrochloride Liposome in Combination With 5-FU/LV in Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically or cytologically confirmed solid tumors documented as advanced or metastatic disease;~2. Subjects must be considered relapsed or refractory to standard therapies, have been intolerant to standard therapies, or have refused standard therapy;~3. ECOG: 0-1;~4. Adequate organ and bone marrow function;~5. sign an informed consent.~Exclusion Criteria:~1. Patients with brain malignant tumor or active CNS metastasis;~2. UGT1A1\*28 homozygous mutants;~3. Clinically significant GI disorders;~4. Significant cardiovascular disease;~5. Active infection or uncontrolled fever;~6. Pregnant or breast feeding patients;~7. Allergic to a drug ingredient or component;~8. The investigators determined that other conditions were inappropriate for participation in this clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment group: (Type: EXPERIMENTAL): Irinotecan liposome plus 5-fluorouracil, Leucovorin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient is in a stable, monogamous sexual relationship with the same woman for at least 6 months and plans to maintain this relationship for the duration of the study~* diagnosis of premature ejaculation (PE) according to the criteria of Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) for at least 6 months before study initiation~* history of intravaginal ejaculatory latency time (IELT) of \<2 minutes in at least 3 out of 4 events~* good general health~* patient's partner must have a negative urine pregnancy test at time of screening~Exclusion Criteria:~* Not taken dapoxetine or participated in another study investigating pharmacologic treatment of PE within the last 3 months~* no history of any medical events that are associated with the development of PE~* not taken another investigational drug within 1 month, or used an experimental medical device within 6 months, of study initiation~* no positive diagnosis of depressive or anxiety disorder, manic episode, panic disorder, obsessive-compulsive disorder, posttraumatic stress disorder, alcohol abuse and dependence, schizophrenia, or other psychotic disorders~* no known allergy or hypersensitivity to selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Male and female patients with a diagnosis of type 2 diabetes mellitus and previously treated with metformin alone or with metformin and one other oral antidiabetic drug~2. Glycosylated haemoglobin (HbA1c) 6.0 - 9.0% at screening for patients treated with metformin and one other oral antidiabetic drug~3. HbA1c 6.5 - 10.0% at screening for patients treated with metformin alone~4. HbA1c 6.5 - 10.0% at beginning of the placebo run-in phase~Exclusion criteria:~1. Myocardial infarction, stroke or transient ischemic attack (TIA)~2. Impaired hepatic function~3. Renal failure or renal impairment~4. Treatment with rosiglitazone or pioglitazone within 6 months prior to screening~5. Treatment with insulin or glucagon-like peptide 1 (GLP-1) analogue/antagonists within 3 months prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- BI 1356 5mg, once daily (Type: EXPERIMENTAL): patient to receive a tablet containing 5mg BI 1356 plus one (two in US) inactive placebo capsule matching Glimepiride
- Glimepiride (Type: ACTIVE_COMPARATOR): patient to receive 1mg or 2mg or 3mg (not in US) or 4mg Glimepiride capsule plus one inactive placebo tablet matching BI 1356 (plus one inactive placebo capsule in US)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit Smoking

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must have stable, documented cardiovascular disease (including at least one of the following diagnosed \> 2 months prior to the Screening visit - angina, myocardial infarction (MI), revascularization, transient ischemic attack (TIA), and peripheral vascular disease (PVD).~* Participants that smoke \> 10 cigarettes / day.~Exclusion Criteria:~* Participants with unstable cardiovascular disease~* Cardiovascular events in the past 2 months~* Moderate or severe chronic obstructive pulmonary disease (COPD)

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): None
- varenicline (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete